Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Nov;76(5):1851–1856. doi: 10.1172/JCI112178

Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.

S Hirschel-Scholz, J Caverzasio, J P Bonjour
PMCID: PMC424224  PMID: 2997292

Abstract

Hypocalcemia has been observed in patients receiving WR-2721 [S-,2-(3-aminopropylamino)-, ethylphosphorothioic acid]. WR-2721 is a compound that, after being dephosphorylated, provides protection of normal tissues against radio- and chemotherapy. The hypocalcemic response was accompanied by a decrease in the plasma level of parathyroid hormone (PTH) and by hypomagnesemia. Our present studies in rats on the mechanism of the hypocalcemic effect of WR-2721 indicate that: (a) The phosphorylated and dephosphorylated form of WR-2721 induced an equal dose-dependent decrement in plasma calcium. (b) In intact rats a maximal hypocalcemic dose of WR-2721 reduced urinary cyclic AMP excretion from 70.5 +/- 6.3 to 38.2 +/- 3.1 pmol/ml glomerular filtration rate (GFR), a level comparable to that observed (35.9 +/- 5.2 pmol/ml GFR) in thyroparathyroidectomized (TPTX) rats. (c) WR-2721 given to TPTX rats did not significantly interfere with the calcemic effect of bovine PTH 1-34 infused at 2.5 IU/h. Likewise, the drug did not impair the PTH actions on the renal Ca and inorganic phosphate (Pi) handling, and on the urine cyclic AMP excretion. (d) In TPTX rats made normocalcemic by low Pi diet, the hypocalcemic effect of WR-2721 was only about 25% of that observed in intact animals. However, it was associated with increased urine Ca per milliliter GFR, indicating a PTH-independent inhibitory effect on tubular Ca reabsorption. (e) In WR-2721-treated intact rats, prevention of hypomagnesemia by infusing magnesium chloride did not reduce hypocalcemia. In conclusion, the hypocalcemic effect of WR-2721 is not dependent upon the presence of a phosphate group in the molecule and is not causally related to hypomagnesemia. WR-2721 appears to be a unique hypocalcemic pharmacologic agent with strong inhibitory activity on PTH secretion and additional PTH-independent action on renal Ca reabsorption.

Full text

PDF
1851

Images in this article

1853Image
on p.1853
1853Image
on p.1853
1853Image
on p.1853
1854Image
on p.1854

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bilezikian J. P. The medical management of primary hyperparathyroidism. Ann Intern Med. 1982 Feb;96(2):198–202. doi: 10.7326/0003-4819-96-2-198. [DOI] [PubMed] [Google Scholar]
  2. Bonjour J. P., Preston C., Fleisch H. Effect of 1,25-dihydroxyvitamin D3 on the renal handling of Pi in thyroparathyroidectomized rats. J Clin Invest. 1977 Dec;60(6):1419–1428. doi: 10.1172/JCI108903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brown B. L., Albano J. D., Ekins R. P., Sgherzi A. M. A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate. Biochem J. 1971 Feb;121(3):561–562. doi: 10.1042/bj1210561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Durand R. E. Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br J Cancer. 1983 Mar;47(3):387–392. doi: 10.1038/bjc.1983.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Glaser B., Kraiem Z., Rotem M., Gonda M., Bernheim J., Sheinfeld M. Effect of acute cimetidine administration on indices of parathyroid hormone action in healthy subjects and patients with primary and secondary hyperparathyroidism. J Clin Endocrinol Metab. 1984 Nov;59(5):993–997. doi: 10.1210/jcem-59-5-993. [DOI] [PubMed] [Google Scholar]
  6. Glover D., Riley L., Carmichael K., Spar B., Glick J., Kligerman M. M., Agus Z. S., Slatopolsky E., Attie M., Goldfarb S. Hypocalcemia and inhibition of parathyroid hormone secretion after administration of WR-2721 (a radioprotective and chemoprotective agent). N Engl J Med. 1983 Nov 10;309(19):1137–1141. doi: 10.1056/NEJM198311103091901. [DOI] [PubMed] [Google Scholar]
  7. Hirschel-Scholz S., Jung A., Fischer J. A., Trechsel U., Bonjour J. P. Suppression of parathyroid secretion after administration of WR-2721 in a patient with parathyroid carcinoma. Clin Endocrinol (Oxf) 1985 Sep;23(3):313–318. doi: 10.1111/j.1365-2265.1985.tb00229.x. [DOI] [PubMed] [Google Scholar]
  8. Hugi K., Bonjour J. P., Fleisch H. Renal handling of calcium: influence of parathyroid hormone and 1,25-dihydroxyvitamin D3. Am J Physiol. 1979 Apr;236(4):F349–F356. doi: 10.1152/ajprenal.1979.236.4.F349. [DOI] [PubMed] [Google Scholar]
  9. Ljunghall S., Akerström G., Rudberg C., Wide L., Johansson H. Cimetidine in primary hyperparathyroidism. Lancet. 1980 Aug 30;2(8192):480–480. doi: 10.1016/s0140-6736(80)91916-9. [DOI] [PubMed] [Google Scholar]
  10. Monson J. P., Beer M., Boucher B. J., Cohen R. D. Propranolol in primary hyperparathyroidism. Lancet. 1979 Apr 21;1(8121):884–884. doi: 10.1016/s0140-6736(79)91308-4. [DOI] [PubMed] [Google Scholar]
  11. Robinson M. F., Hayles A. B., Heath H., 3rd Failure of cimetidine to affect calcium homeostasis in familial primary hyperparathyroidism (multiple endocrine neoplasia, type 1). J Clin Endocrinol Metab. 1980 Oct;51(4):912–914. doi: 10.1210/jcem-51-4-912. [DOI] [PubMed] [Google Scholar]
  12. Vora N. M., Kukreja S. C., Williams G. A., Hargis G. K. Parathyroid hormone secretion: effect of beta-adrenergic blockade before and after surgery for primary hyperparathyroidism. J Clin Endocrinol Metab. 1981 Sep;53(3):599–601. doi: 10.1210/jcem-53-3-599. [DOI] [PubMed] [Google Scholar]
  13. Yuhas J. M. Biological factors affecting the radioprotective efficiency of S-2-[2-aminopropylamino] ethylphosphorothioic acid (WR-2721). LD50(3)) doses. Radiat Res. 1970 Dec;44(3):621–628. [PubMed] [Google Scholar]
  14. Yuhas J. M. Protective drugs in cancer therapy: optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):513–517. doi: 10.1016/0360-3016(82)90673-3. [DOI] [PubMed] [Google Scholar]
  15. Yuhas J. M., Spellman J. M., Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 1980 Fall;3(3):211–216. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES